Search
Displaying 261–270 of 585 for “Retinitis pigmentosa”
-
Phase 3 Clinical Trial of NAC Launched for RP Patients
Research NewsThe drug is thought to work independent of the mutated gene causing RP.
-
ViGeneron Launches Clinical Trial of Gene Therapy for RP Caused by CNGA1 Mutations
Research NewsThe gene therapy is administered using a less-invasive intravitreal injection.
-
Ocugen to Launch Phase 3 Clinical Trial of Modifier Gene Therapy for RP
Research NewsThe emerging treatment is designed to work independent of the patient’s mutated gene.
-
Nanoscope Plans to Apply for FDA Approval for its Optogenetic Therapy
Research NewsThe company reported positive two-year results for its Phase 2 clinical trial of MCO-010.
-
VISIONS 2024, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
VISIONS 2024, the global conference of the Foundation Fighting Blindness, provides an excellent opportunity to connect with others from the blind and low vision community and learn about the latest research advancements, products and services for members of our community.
-
jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
Research NewsKnown as retinal progenitors, the company’s jCells® are designed to preserve photoreceptors in people with retinitis pigmentosa (RP) and other retinal diseases.
-
Research News
The company plans to begin a Phase 2/3 clinical trial for the treatment during the first half of 2024.
-
Research News
Known as antisense oligonucleotides, the treatments performed encouragingly in ProQR’s clinical trials
-
NY Researcher’s App Transforms Commuting for the Visually Impaired
Beacon StoriesJohn-Ross Rizzo, a dedicated New York-based researcher, was confronted with life-altering news at a young age when he was diagnosed with choroideremia. Driven by the obstacles he faced due to his condition, he now stands as a key figure leading the development of advanced assistive technology, with the goal of reshaping the daily commutes of those with low vision and blindness.
.png)
